Relation of Interferon Therapy and Hepatocellular Carcinoma in Patients with Chronic Hepatitis C

Imai, Yumiko; Kawata, Satoshi; Tamura, Shinji; Yabuuchi, Iwao; Noda, Shuzo; Inada, Masami; Maeda, Yukihide; Shirai, Yoshio; Fukuzaki, Takayuki; Kaji, Itaru; Ishikawa, Hideki; Matsuda, Yukihiko; Nishikawa, Masahiro; Seki, Kouichi; Matsuzawa, Yūji

doi:10.7326/0003-4819-129-2-199807150-00005

Cited by 327 publications

(276 citation statements)

References 25 publications

Supporting

Mentioning

263

Contrasting

Unclassified

Order By: Relevance

“…Thus, there is no sensitive and quantitative evaluation method for the extent of fibrosis in liver cirrhosis. Even if chronic hepatitis has already progressed to cirrhosis, it is possible to reduce the risk of hepatocarcinogenesis and improve prognosis if fibrosis could be regressed by eradicating the causative virus by IFN or other anti-viral drugs (18)(19)(20)(21)(22).…”

Section: Discussionmentioning

confidence: 99%

Regression of Liver Fibrosis in Cases of Chronic Liver Disease Type C: Quantitative Evaluation by Using Computed Image Analysis

et al. 2004

View full text Add to dashboard Cite

Object It was reported that the liver fibrosis is reduced in patients with chronic liver disease type C after eradication of HCV. Degree of fibrosis was expressed by the classical fibrosis scoring system (F0-F4) at present. However a change of subtle reduction of fibrosis cannot be expressed in its fibrosis score and thus we measured an area of fibrosis and compared detailed change of the fibrosis area in paired liver biopsy.Methods For quantitative assessment of liver fibrosis, we measured an area of fibrosis using computed digital image analysis and pursued the rate of a fibrosis area for whole biopsied liver tissue of 25 patients with HCV infection (20 complete response patients to IFN therapy who showed viral eradication: CR and 5 non-treated ones with IFN but had conservative therapy: CT).Results In CR group, fibrosis rate was 7.2±1.5% before therapy, 2.7±0.5% after the therapy and they were significantly regressed. In CT group, fibrosis rate was 8.4±4.3% at the first biopsy, 15.9±7.7% at the second biopsy.Conclusions Regression of liver fibrosis could be confirmed in patients with virologic response to IFN even in patients with liver cirrhosis. Our quantitative evaluation provided information superior to that obtained by the classical fibrosis staging score system.

show abstract

Section: Discussionmentioning

confidence: 99%

Regression of Liver Fibrosis in Cases of Chronic Liver Disease Type C: Quantitative Evaluation by Using Computed Image Analysis

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Support for the possibility that maintenance therapy might inhibit disease progression had come from a 2-year study of interferon maintenance therapy in a U.S. population 23 . Additionally, several early reports suggested that interferon therapy reduced the development of HCC in Japanese and Italian patients with chronic hepatitis C [14][15][16][17] . Following initiation of the HALT-C Trial in 2000, numerous additional studies were published that addressed the issue of antiviral treatment and development of HCC, leading Craxi and Camma to perform a meta-analysis in 2005 of the then-existing studies 24 .…”

Section: Discussionmentioning

confidence: 99%

“…Data from several previous studies, mostly from Japan, suggested that long-term treatment with interferon-based regimens slowed progression of fibrosis and reduced the occurrence of HCC in persons with chronic HCV infection [14][15][16][17] . To determine whether these results apply also in the U.S., we undertook the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial.…”

Section: Introductionmentioning

confidence: 98%

Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease

Harnois¹

2009

Yearbook of Gastroenterology

View full text Add to dashboard Cite

show abstract

“…Studies demonstrate that the risk of HCC in individuals who achieve virologic cure is reduced compared to nonresponders (74)(75)(76)(77)(78). In a multicenter retrospective study of 479 HCV patients treated with IFN or PEG-IFN with or without ribavirin, 142 (29.6%) subjects had a sustained response (74).…”

Section: Hcc In Patients Treated With Ifn Based Therapymentioning

confidence: 99%

Viral hepatitis and hepatocellular carcinoma: etiology and management

Zamor

deLemos

Russo

2017

J. Gastrointest. Oncol.

121

View full text Add to dashboard Cite

Hepatitis B virus (HBV) risk and hepatocellular carcinoma (HCC) EpidemiologyIt is estimated that over 50% of HCC cases worldwide are related to chronic HBV (1,2). Since the implementation of worldwide HBV vaccination there has been an overall decline in the burden of HBV, yet the HBV burden remains quite high in various parts of the world. There are approximately 350-400 million people across the world infected with HBV, the majority reside in or originate from Asia. Each year HBV accounts for 749,000 new cases of HCC and 692,000 HCC-related deaths (3). The annual incidence of HCC is estimated to be <1% for non-cirrhotic HBV infected patients and 2-3% for those with cirrhosis. Because of worldwide and geographic variations in HBV incidence, the burden of HBV related HCC also varies. Asian-Pacific and sub-Saharan Africa represent the highest incidence of HCC worldwide. Much lower risk of HBV associated HCC is seen in the United States with less than 20% incidence. Due to its diversity, Europe has different areas: low risk (18%) in West and North and high risk (51%) East and South (4). Occult HBV or subclinical infection as defined by detectable HBV DNA in the liver but hepatitis B surface antigen (HBsAg) seronegativity is now recognized as increased risk for HCC. The risk is most notable in those over the age of 50 (5,6). Recently published data reveal that in China, the age-standardized death due to HBV-related HCC and cirrhosis in 2013 was 10.95 and 4.91 per 100,000 people (7). Fifty-five percent of all HCC cases worldwide are reported from China (8).In 1991, the WHO recommended the integration of the HBV vaccine into national immunization programs in countries with an HBV carrier prevalence of 8% or higher by 1995 and in all other countries by 1997 (9). The universal infant vaccination rate in sub-Saharan Africa was initially quite low at 5% in 2000 but increased to 72% by 2012. Parts of the Pacific region had the lowest immunization rates, but by 2012 had increased to the highest rates at 91%. Taiwan has an exceptionally higher This review outlines the various mechanisms and pathophysiology that contributes to this process. There will also be a review on the recommended screening for HCC. Treatment considerations, which are different for these viruses, will be outlined in this review.

show abstract

Relation of Interferon Therapy and Hepatocellular Carcinoma in Patients with Chronic Hepatitis C

Abstract: The incidence of hepatocellular carcinoma was lower in patients with sustained response to interferon therapy than historical controls and nonresponders. Interferon therapy may decrease the risk for hepatocellular carcinoma in patients with chronic hepatitis C.

Cited by 327 publications

References 25 publications

Regression of Liver Fibrosis in Cases of Chronic Liver Disease Type C: Quantitative Evaluation by Using Computed Image Analysis

Regression of Liver Fibrosis in Cases of Chronic Liver Disease Type C: Quantitative Evaluation by Using Computed Image Analysis

Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease

Viral hepatitis and hepatocellular carcinoma: etiology and management

Contact Info

Product

Resources

About